Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV Immunogenicity Study of ACYW135 Meningococcal Conjugate Vaccine (CRM197 Carrier)
CTR20231943Phase 4Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Meningococcal conjugate vaccine quadrivalent in meningococcal meningitis, sponsored by CanSino Biologics Inc.. Started Jul 2023; status: completed.
02
Drugs
Meningococcal conjugate vaccine quadrivalent
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on CTR20231943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231943.